Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:conditionStudied |
gptkb:familial_hypercholesterolemia
|
| gptkbp:controls |
placebo
|
| gptkbp:duration |
52 weeks
|
| gptkbp:endDate |
2014
|
| gptkbp:fullName |
Durable Effects of PCSK9 Antibody Compared with Placebo Study
|
| https://www.w3.org/2000/01/rdf-schema#label |
DESCARTES trial
|
| gptkbp:intervention |
gptkb:monoclonal_antibody
|
| gptkbp:location |
multinational
|
| gptkbp:number |
NCT01516879
|
| gptkbp:participants |
901
|
| gptkbp:principalInvestigator |
Jennifer G Robinson
|
| gptkbp:publishedIn |
gptkb:Lancet
|
| gptkbp:result |
evolocumab significantly reduced LDL cholesterol compared to placebo
LDL cholesterol reduction |
| gptkbp:sponsor |
gptkb:Amgen
|
| gptkbp:startYear |
2012
|
| gptkbp:studiedDrug |
gptkb:evolocumab
|
| gptkbp:bfsParent |
gptkb:evolocumab
|
| gptkbp:bfsLayer |
8
|